Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $218.00

Krystal Biotech (NASDAQ:KRYS) had its target price hoisted by Chardan Capital from $212.00 to $218.00 in a research note released on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts have also issued reports on KRYS. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday. Citigroup upped their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Stock Up 2.9 %

NASDAQ KRYS opened at $187.86 on Thursday. The stock has a market cap of $5.41 billion, a PE ratio of 62.83 and a beta of 0.84. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The business has a 50 day moving average price of $157.85 and a two-hundred day moving average price of $175.28.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. During the same quarter in the prior year, the business earned $0.30 EPS. Krystal Biotech’s quarterly revenue was up 116.4% compared to the same quarter last year. Sell-side analysts anticipate that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech in the third quarter worth $40,000. Values First Advisors Inc. bought a new position in shares of Krystal Biotech in the third quarter worth $53,000. GF Fund Management CO. LTD. bought a new position in shares of Krystal Biotech in the fourth quarter worth $95,000. Huntington National Bank grew its stake in shares of Krystal Biotech by 97.6% in the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after purchasing an additional 283 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Krystal Biotech by 242.4% in the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after purchasing an additional 412 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).